Effects of subthalamic nucleus deep brain stimulation on the neuropsychological function of patients with Parkinson's disease: A meta-analysis

郑文韬,欧阳佳,许可,苗泽宇,刘如恩
DOI: https://doi.org/10.3760/cma.j.cn112050-20191228-00546
2020-01-01
Abstract:Objective:To comprehensively evaluate the effects of subthalamic nucleus deep brain stimulation (STN-DBS) on the neuropsychological function of patients with Parkinson′s disease (PD) with meta analysis.Methods:Randomized controlled trials (RCTs) of STN-DBS for PD were retrieved from PubMed, Embase, Cochrane library, CNKI, WanFang, VIP from the establishment of the databases to December 1st, 2019 using the following key words: subthalamic nucleus, STN, deep brain stimulation, DBS, Parkinson disease, neuropsychological. The Jadad scale was applied to evaluate the quality of the studies. Meta-analysis was performed using the software of Revman 5.3 to evaluate the effects of STN-DBS on the neuropsychological function in patients with PD.Results:A total of 5 studies with Jadad score≥4 involving 740 PD patients were included. Meta-analysis showed that compared with those receiving drug therapy alone, patients undergoing STN-DBS had significantly better results in terms of the Beck Depression Inventory scores ( SMD=-0.27, 95% CI: -0.47-0.06, P=0.010). In contrast, STN-DBS significantly reduced the scores of verbal fluency (phonemic fluency: SMD=-0.44, 95% CI: -0.63-0.25, P<0.001; semantic fluency: SMD=-0.29, 95% CI: -0.47-0.10, P=0.002). There were no significant differences between pre- and post-treatment according to the indexes including Mattis Dementia Rating Scale (MDRS), Wechsler Adult Intelligence Scale (WAIS) Digit Span, Wisconsin Card Sorting Test (WCST), Trail Making Test Part A (TMT-A), Boston Naming Test (BNT) in both groups (MDRS: SMD=0.03, 95% CI: -0.15-0.21, P=0.72; WAIS Digit Span forward: SMD=0.06, 95% CI: -0.16-0.28, P=0.61; WAIS Digit Span backward: SMD=-0.14, 95% CI: -0.36-0.08, P=0.21; WCST categories achieved: SMD=-0.23, 95% CI: -0.57-0.11, P=0.19; TMT-A: SMD=-0.08, 95% CI: -0.31-0.15, P=0.50; Boston Naming Test: SMD=-0.03, 95% CI: -0.29-0.24, P=0.85). Conclusions:STN-DBS may improve the depressive symptoms of patients with PD without affecting the overall cognitive function. However, there seems to be postoperative decline of verbal fluency.
What problem does this paper attempt to address?